This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA Program 93.855 Allergy and Infectious Diseases Research, provides $1,162,224 to the University of Pittsburgh to optimize an oral BCG vaccine regimen, compare the efficacy of oral BCG to other BCG administration routes, and identify correlates of vaccine-induced protection against tuberculosis (TB) infection. The project aims to advance the development of a more effective vaccine against...
This Project Grant award, valued at $749,192.00 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to better understand the molecular basis for differences in efficacy between different sub-strains of the Bacillus Calmette-Guérin (BCG) vaccine used to prevent tuberculosis (TB). The award will fund two key efforts: 1) Comparing animal model biomarkers of BCG sub-strain...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to evaluate the safety, immunogenicity, and efficacy of an attenuated Mycobacterium tuberculosis (MTB) vaccine candidate in the setting of HIV co-infection. The $905,998 award to the Texas Biomedical Research Institute aims to directly test the hypothesis that the SIGH-based attenuated MTB vaccine...
This Project Grant award for $650,000 was provided by the U.S. Department of Agriculture's (USDA) Agriculture and Food Research Initiative (AFRI) program. The grant supports the development of a novel mucosal vaccine approach to control bovine tuberculosis (BTB) caused by Mycobacterium tuberculosis variant bovis (M. bovis) in livestock and wildlife populations. The principal investigator at the University of Missouri System will engineer immunogenic proteins from the M. tuberculosis complex into...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $817,405.00 to Colorado State University and its subrecipient, the University of Tennessee Health Science Center, to develop new drug regimens for treating tuberculosis (TB), including both drug-sensitive and multidrug-resistant strains. The key objectives are to: 1) manufacture and characterize inhalable dry...
This Project Grant award of $600,000 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of an inhalable dry powder formulation of D29 mycobacteriophages for the treatment of tuberculosis (TB). The awardee, Via Therapeutics, LLC, aims to use thin-film freeze-drying technology to create a stable, aerosolizable powder that can efficiently deliver viable phages to the lungs to kill...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $278,390 to The Regents of the University of California, San Francisco (UCSF) to determine the value of the ESAT-6 antigen in M. tuberculosis infection and vaccines. The goal is to understand whether ESAT-6-specific CD4 T cell responses are beneficial, detrimental, or neutral in tuberculosis (TB) infection, and whether...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $256,000 will develop Recombinant BCG as a novel immunoadjuvant for viral infections. The awardee, Oncosting LLC located in Baltimore, Maryland, will optimize media and lyophilization manufacturing of BCG-STING, evaluate its immunological effects as an adjuvant for H1N1 influenza vaccination, and assess its protective effects as an H1N1 vaccine adjuvant. By adding stimulator of...
This Project Grant award of $1,011,348 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how interactions between Mycobacterium tuberculosis (M.TB) and the human alveolar environment, particularly in people living with HIV, impact the early stages of TB infection. The key objectives are to: 1) Determine how M.TB exposure to alveolar lining fluid from people living with...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $800,200 to study the mechanisms of interferon-gamma (IFN-γ)-independent T cell and B cell-mediated protection against tuberculosis (TB) in humans. The research aims to elucidate the IFN-γ-independent T cell response and characterize the B cell, antibody, and T follicular helper (Tfh) cell responses in...